{
    "clinical_study": {
        "@rank": "25102", 
        "arm_group": {
            "arm_group_label": "Ancillary-Correlative (sample collection)", 
            "description": "Patients undergo collection of tissue biopsy, blood, buccal swab, saliva, and urine at baseline."
        }, 
        "biospec_descr": {
            "textblock": "Tissue, blood, buccal mucosa, saliva, urine"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This pilot research trial studies collecting, analyzing, and storing samples from patients\n      with metastatic, triple negative breast cancer receiving cisplatin. Studying samples of\n      tissue, blood, buccal swab, saliva, and urine in the laboratory from patients receiving\n      cisplatin may help doctors learn more about changes that occur in DNA and identify\n      biomarkers related to cancer."
        }, 
        "brief_title": "Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Cisplatin", 
        "condition": [
            "Estrogen Receptor-negative Breast Cancer", 
            "HER2-negative Breast Cancer", 
            "Progesterone Receptor-negative Breast Cancer", 
            "Recurrent Breast Cancer", 
            "Stage IV Breast Cancer", 
            "Triple-negative Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To establish the safety and feasibility of collecting, analyzing and storing panomic and\n      other data from serially monitored patients with cancer in a manner that is scientifically\n      useful.\n\n      SECONDARY OBJECTIVES:\n\n      I. To determine whether genetic changes associated with cisplatin resistance can be\n      identified, to explore patient perceptions regarding panomic data and its application to\n      cancer treatment, and to apply other technologies to the characterization of patient tumors\n      as they become available.\n\n      OUTLINE:\n\n      Patients undergo collection of tissue biopsy, blood, buccal mucosa, saliva, and urine at\n      baseline."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients will have metastatic triple negative breast cancer (TNBC) and are about to\n             receive treatment with single agent cisplatin\n\n          -  Measurable disease including bone disease as determined by physical exam or imaging\n\n          -  Patients must have tumor suitable for biopsy (as assessed by trained specialists in\n             radiology); patients must be medically fit and willing to undergo repeated tissue\n             biopsies or surgical procedures to get tumor tissue\n\n          -  Written informed consent obtained from subject and ability for subject to comply with\n             the requirements of the study\n\n          -  Procedure-specific signed informed consent prior to initiation of any study-related\n             procedures\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (or a Karnofsky\n             performance status of >= 50%)\n\n          -  Agree to allow their de-identified clinical and laboratory data to be posted to\n             publicly available databases such as database of Genotypes and Phenotypes (dbGaP)\n\n          -  Minorities are included in this protocol\n\n          -  Patients with a prior history of malignancy remain eligible\n\n          -  Patients with an inherited cancer syndrome or a medical history suggestive of an\n             inherited cancer syndrome remain eligible\n\n        Exclusion Criteria:\n\n          -  It is at the enrolling study oncologist's discretion to decide if a patient is not\n             fit enough to undergo tissue biopsy; presence of a condition or abnormality that in\n             the opinion of the Investigator would compromise the safety of the patient or the\n             quality of the data\n\n          -  Significant bleeding disorder\n\n          -  Pregnant, breastfeeding, or unwilling to practice birth control during participation\n             in the study\n\n          -  Prisoners\n\n          -  Inability to give informed consent\n\n          -  Known brain metastases that haven't been treated\n\n          -  Bevacizumab treatment within 4 weeks prior to biopsy\n\n          -  Anticoagulation therapy, unless reversed at the time of biopsy\n\n          -  Patients with a life expectancy of less than 6 months\n\n          -  Prior treatment with platinum-based chemotherapy for TNBC"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with metastatic triple negative breast cancer treated at Fred Hutchinson Cancer\n        Research Center/University of Washington Cancer Consortium"
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01957514", 
            "org_study_id": "8132", 
            "secondary_id": [
                "NCI-2013-01654", 
                "ITOMIC-001", 
                "UW13022", 
                "8132", 
                "P30CA015704"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Ancillary-Correlative (sample collection)", 
            "description": "Correlative studies", 
            "intervention_name": "laboratory biomarker analysis", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 3, 2014", 
        "location": {
            "contact": {
                "last_name": "Anthony Blau", 
                "phone": "206-685-6873"
            }, 
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98109"
                }, 
                "name": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium"
            }, 
            "investigator": {
                "last_name": "Anthony Blau", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Intensive Trial of OMics in Cancer (ITOMIC) - Intensive Longitudinal Monitoring in Patients With Triple-Negative Breast Cancer", 
        "overall_official": {
            "affiliation": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium", 
            "last_name": "Anthony Blau", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety of performing multiple biopsies over time measured by the presence of biopsy-related complications, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v)4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Within 1 week of biopsy"
            }, 
            {
                "measure": "Infrastructure for acquiring, storing, retrieving and analyzing panomic data from clinical tumor specimens in a clinically relevant timeframe", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01957514"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number or frequencies of biopsies", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Molecular changes associated with treatment response or resistance", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Development and improvement of infrastructure for storing and working with data from patient biopsies", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Removal of any unnecessary biopsies or generation of redundant data", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Methods required to analyze and integrate data across patients and with data from the public domain", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Change in patient perceptions regarding panomic data and its application to cancer treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 2 years"
            }, 
            {
                "measure": "Develop process improvements by monitoring the yield of successfully performing various types of analyses from biopsy specimens as well as the time frame necessary for returning reports to patients and their oncologists", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "source": "University of Washington", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Washington", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}